ArticleScientific reports2025
Comparison of antimicrobial resistance in Pseudomonas aeruginosa from intensive care and non-intensive care units and its impact on treatment decisions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Genomic and Phenotypic Insights into Carbapenemase-Mediated Resistance and Clonal Diversity of Pseudomonas aeruginosa Clinical Isolates from Southern Brazil.Current microbiology · 2026Article
- Integrative Systems-Level Transcriptomic Network Analysis Identifies Candidate Genes Associated with Biofilm Formation and Virulence inInternational journal of molecular sciences · 2026Article
- Distribution, antibacterial resistance, biofilm formation, and risk factors associated with carbapenemase-producing gram-negative bacteria in ICU patients.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges.Microorganisms · 2026Review
- Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.BMC infectious diseases · 2026Article
- Article
- 5-Fluorouracil modulates motility and biofilm-associated gene expression in Pseudomonas aeruginosa.PloS one · 2026Article
- Essential role of cytochromeFrontiers in cellular and infection microbiology · 2026Article
- Whole genome sequencing of ceftolozane/tazobactam-resistant, XDRFrontiers in cellular and infection microbiology · 2026Article
- Molecular Framework of Multidrug Resistance in Pseudomonas aeruginosa.Current microbiology · 2025Review
- Biocontrol of Phage Resistance inViruses · 2025Review
- A Selective Chromogenic Medium for Detecting Meropenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergence of difficult-to-treat-resistance (DTR) P. aeruginosa has significant implications for the selection of empirical therapies. This study aims to compare antimicrobial resistance of P. aeruginosa from ICU and non-ICU patients and to discuss empirical treatment options. Three-hundred-nine P. aeruginosa strains isolated from hospitalized patients in 2023 were included. Antimicrobial susceptibility results for six classes with potential activity against P. aeruginosa were collected. Resistance between strains isolated from ICU and non-ICU was compared. Among 309 strains, 30% were isolated from ICU patients, while 70% from non-ICU. Resistance to ciprofloxacin was significantly higher in non-ICU compared to ICU patients (64% vs. 15%, p-value = 0.0001). Resistance to piperacillin-tazobactam was higher in ICU compared to non-ICU patients (36% vs. 22%, p-value = 0.012). Prevalence of DTR P. aeruginosa was similar between the two groups (21% in ICU and 19% in non-ICU patients). Joint resistance to imipenem and ceftazidime was more prevalent in ICU patients (27% vs. 10%, p-value 0.0001). Additionally, carbapenemase-producing strains were more frequent in ICU patients (20% vs. 5%, p-value = 0.0001). Ceftolozane-tazobactam, whose effectiveness against DTR P. aeruginosa remains preserved, as empirical treatment, would improve its adequacy by 21% in ICU and 19% in non-ICU patients, compared to the currently recommended first-line treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.